Shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) have been given an average rating of “Buy” by the twelve research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $42.00.

Several research analysts have recently commented on the stock. Northland Securities began coverage on shares of Adamas Pharmaceuticals in a report on Wednesday. They issued an “outperform” rating for the company. Noble Financial lifted their price objective on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Evercore ISI began coverage on shares of Adamas Pharmaceuticals in a research report on Monday, October 30th. They issued an “outperform” rating on the stock. ValuEngine downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 13th. Finally, Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th.

Several hedge funds have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. raised its position in shares of Adamas Pharmaceuticals by 639.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 850,165 shares of the specialty pharmaceutical company’s stock worth $17,998,000 after buying an additional 735,165 shares in the last quarter. Granite Point Capital Management L.P. raised its position in shares of Adamas Pharmaceuticals by 26.6% during the 3rd quarter. Granite Point Capital Management L.P. now owns 333,515 shares of the specialty pharmaceutical company’s stock worth $7,061,000 after buying an additional 70,000 shares in the last quarter. Axiom International Investors LLC DE raised its position in shares of Adamas Pharmaceuticals by 134.1% during the 3rd quarter. Axiom International Investors LLC DE now owns 236,209 shares of the specialty pharmaceutical company’s stock worth $5,001,000 after buying an additional 135,297 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Adamas Pharmaceuticals by 13,028.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after buying an additional 135,235 shares in the last quarter. Finally, FNY Partners Fund LP bought a new stake in shares of Adamas Pharmaceuticals during the 3rd quarter worth about $231,000. Institutional investors own 79.45% of the company’s stock.

Adamas Pharmaceuticals (NASDAQ ADMS) traded up $2.03 during midday trading on Thursday, hitting $37.15. 1,209,710 shares of the stock traded hands, compared to its average volume of 521,585. Adamas Pharmaceuticals has a 1-year low of $13.50 and a 1-year high of $38.22. The company has a quick ratio of 8.32, a current ratio of 8.35 and a debt-to-equity ratio of 0.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.01) by ($0.03). During the same quarter last year, the business earned ($0.66) EPS. Adamas Pharmaceuticals’s revenue for the quarter was down 99.3% compared to the same quarter last year. equities analysts forecast that Adamas Pharmaceuticals will post -3.87 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/adamas-pharmaceuticals-inc-adms-receives-average-recommendation-of-buy-from-brokerages.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.